12:00 AM
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zertane tramadol hydrochloride: Phase III start

Ampio said FDA accepted POPE as a co-primary endpoint for a U.S. Phase III trial of Zertane. The company said it is seeking to monetize the product through an acquisition or through licensing deals and that the trial start...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >